



We help brands succeed in the era of the **Patient-as-Payer**.

3 reasons impacting


why **patients** are increasingly **payers** for their prescription medications:



Even with “good” market access coverage, most brands still have gaps or utilization management hurdles that patients must overcome.



GoodRx helps **1 in 4 Americans** get the medications they need at a price they can afford by bridging the gaps in traditional insurance coverage.



According to a 2024 GoodRx survey, **33% of Americans** had a prescription sent to the pharmacy that was ultimately **not filled**.

GoodRx has saved Americans **\$75 billion** on medications since 2011.

Source: GoodRx, “The GoodRx Effect,” 2024.



Is your **Gross-to-Net** standing in the way of your **Go-to-Market** success?

Factoring in **copay assistance with rising rebates**, many brands are under water on a net basis, particularly in the first quarter of each year.

GoodRx can deliver an alternative access and affordability strategy and provide manufacturers a direct line-of-sight to unit economics.

More than 70 brands


leverage our reach and scale to drive Rx fills using a manufacturer-sponsored, cash buy down program.



GoodRx delivers results for patients, HCPs, and your brand.



For a mature diabetes treatment, GoodRx met high-intent patients at the point of conversion and drove a 286% lift in new to brand prescriptions (NBRx).



Our HCP campaign for a mature CNS brand showed significant increases in market share and prescriber penetration, while showing a directional increase in NRx volume among total HCPs.




The GoodRx HCP campaign for this biologic for Crohn's disease showed significant increases in new treatments volume and market share among total HCPs.

Sources: Internal GoodRx data and IQVIA analysis, August-December 2023; Internal GoodRx data and IQVIA analysis, October-December 2023; and Internal GoodRx data and IQVIA analysis, April 2023-March 2024.

Results that redefine what Good looks like.

GoodRx point-of-sale (POS) program drove incremental Rx growth for a mature diabetes brand.



Source: IQVIA Market Share Library, Volume Trend, September-December 2023.

GoodRx's proven access and affordability solutions for brands and portfolios include:

- ✓ Direct-to-consumer cash discount sponsored by the pharma manufacturer
- ✓ Manufacturer copay integrations
- ✓ Enrollment for patient services programs
- ✓ Extending your hub services to reach eligible patients



GoodRx's healthcare platform offers pharma companies a more seamless and scalable way to **deliver integrated access & affordability solutions**.

[LEARN MORE](#)